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A B S T R A C T
Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment in hemophilia. Its
widespread application has led to a dramatic decrease in morbidity and mortality in patients, with concomitant
improvement of quality of life. However, dosing is challenging and costs are high. This review discusses beneﬁts
and limitations of pharmacokinetic (PK)-guided dosing of replacement therapy as an alternative for current
dosing regimens. Dosing of CFC is now primarily based on body weight and based on its in vivo recovery (IVR).
Beneﬁts of PK-guided dosing include individualization of treatment with better targeting, more ﬂexible blood
sampling, increased insight into association of coagulation factor levels and bleeding, and potential overall
lowering of overall costs. Limitations include a slight burden for the patient, and availability of closely colla-
borating, experienced clinical pharmacologists.
1. Hemophilia and current treatment
1.1. Background of the disease
Hemophilia A and B are X-linked inherited bleeding disorders
characterized by deﬁciencies of factor VIII (FVIII) and factor IX (FIX),
respectively. Prevalence is estimated at 1 in 5000 male births for he-
mophilia A and 1 in 30,000 male births for hemophilia B [1,2]. FVIII
and FIX enhance formation of thrombin and consequently stabilize the
hemostatic clot by increased ﬁbrin formation. Disease severity is clas-
siﬁed according to residual FVIII or FIX coagulation activity in plasma
[3]. Mild hemophilia patients have FVIII or FIX levels of
0.05–0.40 IU mL−1, moderate patients FVIII or FIX levels of
0.01–0.05 IU mL−1 and severe patients FVIII or FIX levels of< 0.01
IU mL−1. Mild hemophilia is characterized by an increased risk of
bleeding after trauma or surgery. Moreover, severe as well as moderate
hemophilia patients suﬀer from spontaneous bleeding or bleeding after
minimal trauma in muscles and/or joints, potentially resulting in dis-
abling arthropathy [4]. Strikingly, bleeding phenotype diﬀers between
hemophilia patients with identical baseline FVIII or FIX levels and is
probably inﬂuenced by inter-individual variation in patient character-
istics such as age, body weight, modifying factors within the hemostatic
system, behavioral factors and daily (sporting) activities and other yet
unidentiﬁed factors [5–10]. In addition, it may be inﬂuenced by inter-
individual variation of half-life of clotting factor concentrates (CFC)
administered either prophylactically or on demand (Table 1).
1.2. Current treatment with replacement therapy
Replacement therapy with CFC can be given to prevent spontaneous
or repetitive bleeding (prophylaxis), or “on demand” to treat acute
bleeding and prevent bleeding at the time of dental or surgical proce-
dures. Current CFCs are either of recombinant or plasma-derived origin.
Prophylaxis is the mainstay of treatment in hemophilia. Its introduction
has dramatically changed the lives of many hemophilia patients.
Consequently, hemophilia has evolved from a crippling disease with a
shortened life expectancy into a disease with a normal life expectancy,
signiﬁcantly less joint arthropathy and acceptable quality of life
[11,12].
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1.2.1. Prophylaxis
Prophylaxis was introduced in 1965 by Ahlberg and is based on the
observation that moderate hemophilia patients with FVIII or FIX levels
above 0.01 IU mL−1 have far fewer joint bleeds and less subsequent
arthropathy [13]. Therefore, it was reasoned that joint bleedings could
be prevented in severe hemophilia by keeping FVIII and FIX levels
above 0.01 IU mL−1. To achieve this, CFCs must be regularly infused
generally two to four times a week in hemophilia A and one to three
times a week in hemophilia B [14–17]. Prophylactic treatment pro-
foundly reduces frequency of bleeding and improves joint status as
demonstrated by Manco Johnson et al. in a randomized controlled trial
[11]. Various guidelines for prophylaxis are available of which Table 2
shows a selection of those most often applied. The eﬃcacy of prophy-
laxis in preventing joint bleedings is largely dependent on maintaining
minimal FVIII and FIX trough levels of 0.01 IU mL−1 in the patient.
Moreover, time spent below trough levels is associated with number of
bleeding events [18]. However, in standard clinical practice, trough
levels are rarely measured and dose and frequency of prophylactic in-
fusions are only adjusted when spontaneous or frequent bleeding oc-
curs.
1.2.2. On demand treatment
When patients are treated “on demand” either for acute bleeding or
in a dental and/or surgical setting, dosing of CFC is aimed to achieve
FVIII and FIX levels above a certain threshold/trough and below a
certain maximum to avoid waste of CFC and high costs without clinical
eﬀect according to various guidelines (Table 3).
More speciﬁcally, when acute bleeding occurs FVIII and FIX peak
levels are generally considered particularly important, although they
are rarely monitored. Targeted peak levels are dependent on both
severity and location of bleeding. In Dutch guidelines [14], FVIII or FIX
peak levels of 0.30 IU mL−1 for minor bleeds, 0.50 IU mL−1 for severe
bleeds and 1.00 IU mL−1 for life threatening bleeds are targeted. In
severe or life threatening bleeds, it is more important to take trough
levels into account. These FVIII and FIX levels are sometimes monitored
but often merely estimated, and maintained based on the opinions of
the treating physician. In the perioperative setting, mainly trough levels
are considered important. Although, at initiation of surgery a speciﬁc
peak FVIII and FIX range is targeted according to all guidelines. Overall,
targeted perioperative FVIII and FIX trough levels depend on the in-
vasiveness of the dental and/or surgical procedure and postoperative
day, with e.g. Dutch guidelines prescribing FVIII or FIX trough levels of
0.80–1.00 IU mL−1 during the ﬁrst 24 h after surgery;
0.50–0.80 IU mL−1 1 to 5 days (24–120 h) after surgery; and
0.30–0.50 IU mL−1 > 5 days after surgery (Table 3).
Peak FVIII and FIX levels are estimated based on average in vivo
recovery (IVR) of FVIII or FIX concentrates and amounts of CFC (IU)
infused per kilogram body weight. This IVR-based dosing originates
from studies that show that each infused unit of CFC per kilogram re-
sults in a mean increase of 0.02 IU mL−1 for FVIII and 0.01 IU mL−1
for FIX [9,19]. Application of this formula only provides a rough esti-
mate of the maximum plasma concentration of FVIII and FIX after in-
fusion. More explicitly, it does not take the pharmacokinetics (PK) of
administered CFC of the individual patient into account, e.g., clearance,
volume of distribution, and half-life (Fig. 1). Application of these PK
parameters results in a more precise estimate of peak FVIII and FIX but
also enables calculation of FVIII or FIX levels and the formulation of
recommendations on frequency and timing of dosing of FVIII and FIX
concentrates.
When describing PK of the various CFC in hemophilia, diﬀerences
Table 1
Factors inﬂuencing bleeding phenotype in hemophilia patients.
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Patient characteristics Hemostatic factors Pharmacokinetics of treatment
Agea FVIII and FIX plasma levels Clearance (Cl)
Body weight FVIII and FIX gene mutation Volume of distribution (Vd)
Other morphometric variables Blood groupa Half-life (T1/2)
Joint status von Willebrand factora In vivo recovery (IVR)
General (muscle) condition Thrombin generation and ﬁbrinolysis
Daily (sporting) activities Unidentiﬁed hemostatic factors
Behavioral factors
Adherence to treatment
Miscellaneous
a Inﬂuencing factor for hemophilia A patients only.
Table 2
Prophylactic dosing regimens for hemophilia A and B.
Prophylaxis Hemophilia A Hemophilia B
Dose (IU kg−1) Frequency dosing (n/
week)
Dose (IU kg−1) Frequency dosing (n/
week)
Utrecht protocol-Dutch (Low dose prophylactic
regimen) [14]
15–30 Three 15–30 Two
Malmö protocol – Nordic (High dose prophylactic
regimen) [17]
25–40 Three 25–40 Two
UKHCDO [16] 25–50 Four Not provideda
WFH [15] According to Utrecht or Malmö
protocol
According to Utrecht or Malmö
protocol
a Recommendations for patients with hemophilia B are not provided given the paucity of published evidence.
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are apparent between products. In both recombinant and plasma-de-
rived FVIII concentrates, average half-life is estimated at 10.4 h [95%
CI 7.5–16.5] in adults and 9.4 h [95%CI 7.4–13.1] in children [20].
This lower half-life in children can be explained by a higher clearance
of FVIII in childhood probably due to the fact that VWF levels increase
with age [21]. Contrastingly, no relationship between age and terminal
half-life is observed for FIX concentrates [22]. Diﬀerences in PK of
current FVIII and FIX concentrates are also signiﬁcant. FVIII clearance
is lower than FIX clearance (2.4–3.4 mL h−1 kg−1 versus
3.8–8.4 mL h−1 kg−1) [23], due to the binding of FVIII to its carrier
protein VWF which protects FVIII from proteolytic degradation
[24,25].
Although, FVIII has a lower clearance in comparison to FIX, FIX has
a much larger volume of distribution (Vd). This larger volume of dis-
tribution of FIX is due to FIX binding to the vascular endothelium and
diﬀusion into interstitial ﬂuid on account of its lower molecular weight
when compared to FVIII (FIX: 57 kDa; FVIII: 280 kDa) [26,27]. This
results in a longer half-life for FIX compared to FVIII (18–34 h and
11–16 h, respectively) as half-life is calculated roughly by t1/2 =
(0.693 ∗ Volume of distribution (Vd))/clearance (CL) [23].
1.2.3. Limitations of current treatment guidelines
Underlying the presently used dosing calculations is the assumption
that all patients demonstrate similar PK of administered CFCs. However
unfortunately, this is not the case. Bjorkman et al. were the ﬁrst to
report the signiﬁcant inter-individual variations in PK after the ad-
ministration of a standard bolus of FVIII or FIX concentrate in a large
population. Signiﬁcant diﬀerences were observed with regard to in vivo
recovery (IVR), clearance and half-life with FVIII half-life varying from
6 to 25 h and FIX half-life from 25 to 56 h between individuals
[8,20,28,29]. Collins et al. showed that the eﬃcacy of prophylactic
treatment is based on time spent above certain FVIII trough levels [30]
and that therefore half-life and frequency of CFC dosing is more im-
portant than IVR of CFCs. Despite these ﬁndings, current treatment
guidelines for replacement therapy are still based on IVR-based dosing
regimens, which do not take the inter-individual variation of pharma-
cokinetics of CFCs into account.
Furthermore, as is observed in the general population, obesity also
increasingly occurs in hemophilia patients [31]. This will result in in
higher FVIII and FIX consumption if prophylactic and on demand
Table 3
Target ranges with peak and trough FVIII and FIX levels and duration of administration according to a selection of available guidelines.
Hemophilia A Hemophilia B
Predeﬁned target ranges (IU mL−1) Duration (days) Predeﬁned target ranges (IU mL−1) Duration (days)
Dutch [14] Major surgery
Preoperative 0.80–1.00 0.80–1.00
Postoperative 0.80–1.00 1 0.80–1.00 1
0.50–0.80 2–5 0.50–0.80 2–5
0.30–0.50 > 6 0.30–0.50 > 6
Minor surgery
Preoperative 0.80–1.00 0.80–1.00
Postoperative > 0.50 Depending on procedure > 0.50 Depending on procedure
Nordic [17] Major surgery
Preoperative 0.70–1.00 0.70–1.00
Postoperative 0.60–0.80 1–3 0.60–0.80 1–3
0.40–0.60 4–6 0.40–0.60 4–6
0.30–0.40 7–9 0.30–0.40 7–9
Minor surgery
Preoperative > 0.50 > 0.50
Postoperative 1–5 depending on procedure 1–5 depending on procedure
WFH [15] No signiﬁcant resource constraints
Major surgery
Preoperative 0.80–1.00 0.60–0.80
Postoperative 0.60–0.80 1–3 0.40–0.60 1–3
0.40–0.60 4–6 0.30–0.50 4–6
0.30–0.50 7–14 0.20–0.40 7–14
Minor surgery
Preoperative 0.50–0.80 0.50–0.80
Postoperative 0.30–0.80 1–5 0.30–0.80 1–5
Signiﬁcant resource constraints
Major surgery
Preoperative 0.60–0.80 0.50–0.70
Postoperative 0.30–0.40 1–3 0.30–0.40 1–3
0.20–0.30 4–6 0.20–0.30 4–6
0.10–0.20 7–14 0.10–0.20 7–14
Minor surgery
Preoperative 0.40–0.80 0.40–0.80
Postoperative 0.20–0.50 1–5 0.20–0.50 1–5
Fig. 1. Description of pharmacokinetic (PK) parameters using non-compartimental
principles. After bolus infusion of clotting factor concentrate, FVIII or FIX plasma levels
increase until the maximum concentration is reached (Cmax). The in vivo recovery (IVR)
is calculated by body weight (BW) (kilograms) x observed increase in FVIII/FIX plasma
levels divided by the dose. Half-life is derived from the clearance (Cl) and volume of
distribution (Vd) and is deﬁned as the time required for the concentration to halve.
Finally, area under de curve (AUC) is the integral of the concentration-time curve.
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treatment is persistently based on body weight and IVR-based dosing
regimens. Importantly, increasing body weight is not linearly associated
with increasing volume of distribution as assumed by IVR-based dosing
regimens [32]. Therefore, these higher costs of treatment may not be
necessary to safeguard hemostasis. Obviously, current global con-
straints of health care budgets, obligates hemophilia communities
worldwide to generate dosing algorithms in hemophilia with optimal
results for patients and minimal costs for society.
Moreover in the perioperative setting, we recently demonstrated
that current dosing leads to signiﬁcantly lower and higher FVIII and FIX
levels than targeted in hemophilia A and B [33], (Hazendonk et al. in
preparation). In moderate and severe hemophilia A patients, a large
proportion of trough and steady state FVIII levels were found to be
below or above predeﬁned target ranges. Speciﬁcally, 45% of FVIII
measurements were below the FVIII target range within ﬁrst 24 h after
surgery and 75% above the target range during hospitalization more
than six days after surgery [33]. Potentially, more optimal maintenance
of perioperative target ranges could result in a reduction of 44% of CFC
consumption, when ignoring logistical aspects of care [33]. In a recent
retrospective study on perioperative management in moderate and se-
vere hemophilia B patients, 60% of FIX measurements were below
target and 59% FIX levels above target during hospitalization more
than six days after surgery (Hazendonk et al. in preparation). Although
the terminology of under- and overdosing suggests putting the patient
at risk which is not the case as perioperative complications were
minimal, these data do underline the limitations of current dosing al-
gorithms primarily based on body weight using IVR-based dosing, as
well as potential cost-eﬀectiveness of alternative algorithms.
2. Pharmacokinetic (PK)-guided dosing in hemophilia
2.1. Principles of PK-guided dosing
To address inter-individual diﬀerences in PK of CFC and to employ
more eﬀective dosing, PK-guided dosing is a potential strategy. PK-
guided dose-calculations are based on individual PK parameters in re-
lationship to the population PK model and obtained by Bayesian ana-
lysis using statistical software (NONMEM®). In a population PK model
for CFC, relationships between dose and achieved FVIII or FIX levels are
described by PK parameters of all individuals in the population under
review. This makes it possible to describe both inter-individual and
intra-individual variability within this population dataset. In general,
an important condition for implementing PK-guided dosing, is that
intra-individual variability is smaller than inter-individual variability.
Identiﬁed covariates explaining variability can be used to further im-
prove constructed models, while unknown factors are labeled as re-
sidual errors. The principal strength of PK-guided dosing is that a po-
pulation PK model not only represents identiﬁed covariates inﬂuencing
PK parameters, but also takes the unknown modiﬁers of PK into account
as they are described by the population data included in the model.
Importantly, Bayesian adaptive dosing is only possible when po-
pulation PK models are representative of the individual patient and her
or his speciﬁc clinical setting. Constructed models should therefore
comprise a wide variation in patient-related (age, body weight, en-
dogenous baseline FVIII/FIX, blood group) and circumstance-related
factors (prophylaxis, on demand dosing during hemostatic challenges
such as acute bleeding and surgery). For example, the recently pub-
lished perioperative FVIII population PK model showed a signiﬁcantly
larger peripheral volume of distribution in comparison to the prophy-
lactic PK model by Bjorkman et al. (1180 mL/68 kg versus 240 mL/
68 kg) [8,34]. Further, to optimize current population models it is
important to include often underrepresented patient populations, such
as children and overweight/obese patients since PK parameters in these
populations may diﬀer signiﬁcantly.
2.2. Construction of individual PK proﬁles and population PK models
Extensive work performed by Bjorkman et al. has made PK-guided
prophylactic dosing with limited blood sampling in hemophilia possible
[35]. Prior to the construction of these population PK models, in-
dividual PK curves were constructed through extensive blood sampling
(> 10 samples), with an obligatory wash-out period, leaving the pa-
tient at potential risk of bleeding. Currently, individual PK proﬁles for
FVIII and FIX can fortunately be constructed with limited blood sam-
pling and without a wash out period (Table 4) [35–37]. Diﬀerent PK
sampling models exist for rFIX and pdFIX, as it was already previously
shown, that the PK of these two products diﬀer [9]. Using Bayesian
analysis and a representative population PK model, individual PK es-
timates can be iteratively updated, providing prophylactic dosing ad-
vice and prediction of achieved FVIII and FIX levels [38].
Perioperatively, several research groups have estimated pre-
operative loading doses of FVIII and FIX after constructing individual
PK proﬁles [39–43]. However, until recently it was not possible to
iteratively dose patients in the perioperative setting owing to the lack of
population PK models for this speciﬁc setting. Construction of perio-
perative PK population models for both moderate and severe hemo-
philia A [34] and B, mild hemophilia A [44] and in the near future for
von Willebrand disease [45] will eventually make this possible for
several bleeding disorders.
The most important covariate in FVIII population PK models for
hemophilia A patients, will most likely be von Willebrand factor (VWF)
as patients with blood group O have 25% lower VWF levels. This is
supported by ﬁndings that blood group O versus non-O is a signiﬁcant
covariate of clearance in the perioperative setting, with 26% higher
clearance rates for patients with blood group O [45]. Furthermore, it
was also shown by Kepa et al. that blood group was associated with
FVIII half-life [46]. However, this eﬀect of blood group O was not
previously observed in a steady state prophylactic setting [47] and
therefore not considered to be a covariate in available prophylactic
population PK models. Most likely, this diﬀerence can be explained by
Table 4
Limited blood sampling strategies to construct individual PK curves.
Bolus infusion
(IUkg−1)
FVIII or FIX measurements
Factor VIII (FVIII)
(Björkman et al.) [35]
50 T= 4, T= 24, T= 48 h
Plasma derived Factor IX
(FIX) (Brekkan et al.)
[37]
50 T = 48, T = 72 h or
T= 54, T= 78 h
Recombinant Factor IX
(FIX) (Preijers et al.)
[36]
100 One sample post infusion,
two samples between
T= 72 and T= 80 h.
The upper panel shows a graphic example of a Factor VIII (FVIII) concentrate PK proﬁle.
A FVIII concentrate bolus is administrated followed by FVIII measurements (red points).
Using a population PK model, FVIII plasma levels (red line) are calculated using in-
dividual PK parameter estimates derived from Bayesian analysis. To estimate FIX PK,
similar principles are applied, although FIX blood sampling occurs at diﬀerent longer time
points as FIX concentrate half-life is longer.
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an increase of VWF due to inﬂicted endothelial damage and its role in
the acute phase reaction after surgery [48].
Pharmacogenomics may also play an important role in the PK of
coagulation factor concentrates. Many genes are known to modify the
hemostatic system and the clearance of coagulation factors. As VWF
serves as carrier protein for FVIII, mutations in the binding site of VWF
to FVIII can result in lower levels of FVIII, also known as von
Willebrand disease type 2N. In addition, the R1205H mutation in the
D3 domain of VWF, also known as VWD Vicenza, results in reduced
plasma VWF levels with ultra-large VWF multimers and therefore
leading to an accelerated clearance of both VWF and FVIII [49]. Al-
though, not only mutations in the VWF gene inﬂuence FVIII levels as
ABO blood group has also a strong relation with FVIII levels. Blood
group O is associated with lower FVIII levels compared to other blood
types even when adjusted for VWF antigen [44]. In addition, the
CHARGE has consortium reported multiple genetic loci in clearance
receptors of VWF and/or FVIII which were associated with FVIII levels,
for example STXBP5 and SCARA5[50]. Furthermore, polymorphisms in
one of the clearance receptors of FVIII/VWF, LRP1 gene, are also as-
sociated with both FVIII and VWF plasma levels [51].
2.3. Beneﬁts of PK-guided treatment
As early as 1997, Carlsson et al. showed beneﬁts of a PK-guided
dosing approach for prophylaxis [7]. This small study was designed as a
randomized cross-over study comparing PK-guided dosing of prophy-
laxis with standard prophylactic dosing in 14 individuals during a
period of two times six months. Strikingly, a reduction of CFC admin-
istration of 30% was achieved. The number of reported bleedings was
similar in both treatment arms [7]. Such a reduction can have a sig-
niﬁcant ﬁnancial impact, since annual costs for replacement therapy in
the Netherlands amount to> 126 million euros [52]. Before drawing
conclusions, however, it is important to prospectively evaluate these
outcomes of PK-guided dosing in adequately designed and powered
studies [53]. Currently, a randomized controlled trial comparing PK-
guided perioperative treatment of CFC in moderate and severe hemo-
philia A patients is in place to analyze the amount of CFC administered,
time spent to achieve targeted FVIII levels, as well as staﬀ investment
and costs, all in accordance with the economic health principles es-
tablished by Hakkaart-van Rooijen [53,54]. This study may result in
clear conclusions regarding the cost eﬀectiveness of PK-guided dosing.
Another beneﬁt of PK-guided dosing is that both prophylactic and
“on demand” dosing will be based on actual FVIII and FIX trough and
peak levels or FVIII and FIX levels predicted by population PK models,
instead of current FVIII and FIX estimates based on IVR-based dosing.
Furthermore, FVIII and FIX sampling can be made ﬂexible and not
necessarily ﬁxed at certain time points before or after infusion, once
models are in place. Moreover, PK-guidance will optimize dosing as
knowledge will increase with regard to the relationship between FVIII
and FIX levels and bleeding in individual patients and patient groups. In
addition, an increase in dosing will not only depend on actual bleeding
and a reduction of dosing can be considered by the treating professional
in consultation with patients and parents. Importantly, the dose and
frequency of CFC of patients on prophylaxis should only be reduced if
clinically justiﬁed and impact should be monitored with regard to
bleeding events, bleeding pattern and joint status (Table 5).
Over time, more exact targeting of FVIII and FIX levels may also
lead to reliably lowering of target levels of treatment. Especially in
hemophilia B, studies and clinical experience suggest that lower target
levels may be acceptable [15,55]. In a recent retrospective study on
perioperative management in moderate and severe hemophilia B pa-
tients, 60% of FIX measurements were below target, without clinical
relevant bleeding and independent of the severity of surgical proce-
dures (Hazendonk et al. in preparation). Srivastava et al. showed that
lower trough FVIII (0.20–0.40 IU mL−1) and FIX (0.15–0.30 IU mL−1)
levels 0–72 h after surgery were not accompanied by bleeding
complications since only one patient experienced bleeding due to a lack
of surgical hemostasis [55]. Furthermore, International WFH guidelines
for perioperative treatment in hemophilia A and B patients recommend
FIX levels 0.20 IU mL−1 lower than FVIII levels (Table 3) [15]. In
countries with signiﬁcant ﬁnancial constraints, even lower FIX target
ranges are suggested [15]. Interestingly, various European guidelines
do not diﬀer regarding perioperative target ranges for hemophilia A
and B [14,17,56] as reported in a survey by the European Therapy
Standardization Board in 2009 [57].
PK-guided dosing will also facilitate individualization of dosing
according to individual lifestyle and activities, therefore achieving true
personalization of treatment. When targeting weekly FVIII and FIX le-
vels, personal activities and preferences should be taken into account,
as bleeding risk is closely related to these factors [58–60]. Moreover,
non-adherence should be discussed as implementation of minimal
dosing schemes may lead to an increased risk of bleeding [61–63].
Patients and families should be aware of time points when factor con-
centrate levels are low or high and consider additional dosing when
bleeding risk is signiﬁcant.
All beneﬁts of PK-guided dosing are also applicable with regard to
upcoming enhanced half-life (EHL) products. Moreover, costs of treat-
ment will directly depend on the dose and frequency of treatment and
therefore on individual PK and population PK parameters. Furthermore,
the ongoing discussion of the association of trough levels and the role of
peak levels with regard to bleeding will be made more transparent. This
is especially relevant in EHL products as higher troughs will be possible
and treatment peaks will be less frequent [64].
2.4. Limitations of PK-guided treatment
Important limitations with regard to PK-guided dosing include the
requirement of close collaboration with a clinical pharmacologist with
expertise in PK modeling. Furthermore, time investments by patients,
parents and medical professionals may be substantial as individual PK
proﬁles must be performed regularly (every three to four years de-
pending on patient characteristics) and perioperative PK-guided itera-
tive dosing requires daily dosing recommendations. Solutions to over-
come these limitations are the availability of web portal-based
consultancies for PK-guided dosing advice, as established by Iorio [21],
for instance, and as developed by a pharmaceutical company for the
prophylactic setting [65]. Both initiatives to implement a closer colla-
boration and to educate both professionals and patients are valuable for
future patient care. Transparency and reliability of the data used to
construct underlying population models are of course of crucial im-
portance in such settings.
3. Future role for PK-guided dosing of factor concentrates in
hemophilia care and research perspective
Replacement therapy has led to the high standard of hemophilia
care in high-income countries. However, recent studies show that
treatment is suboptimal; although bleeding is rare, both under- and
overdosing of CFC occur. We believe that PK-guided dosing as the al-
ternative to body weight and IVR-based dosing, will play an important
role in further individualization of therapy. We have summarized the
anticipated improvements in Table 5.
Future research should include studies prospectively validating
constructed population PK models but also combining PK with phar-
macodynamic data (e.g. bleeding events, global hemostatic test results)
and simulations to determine minimal FVIII and FIX levels required for
adequate hemostasis in the individual patient and in populations. These
data may subsequently support studies aiming at lower target levels in
speciﬁc bleeding disorders.
There are no suggestions that implementation of PK-guided dosing
will lead to an increased risk of inhibitor development. It is well-known
that risk factors of development are peak treatment moments in
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younger children, which is often the case in the perioperative period.
Use of PK-guided dosing may be able to prevent extreme peaks.
However, future studies will be needed to prove such a hypothesis.
4. Conclusion
We believe that PK-guided dosing deserves attention as a means of
ensuring the individualization of treatment in hemophilia since beneﬁts
are signiﬁcant and limitations can be overcome. The burden for patients
and parents appears to be minimal. Accordingly, we call on patients,
medical professionals, clinical pharmacologists, hemostatic laboratories
and pharmaceutical companies to join hands in applying this approach
for all CFCs, in hemophilia and other bleeding disorders requiring CFC
replacement therapy.
Practice points
• Replacement therapy with clotting factor concentrates (CFC) is the
mainstay of treatment in hemophilia.
• However, dosing is challenging and costs are high.
• Current dosing is based on body weight and in vivo recovery (IVR)
of CFC.
• PK-guided dosing will enable individualization of treatment with
better targeting of coagulation factor levels.
Research agenda
• Prospective studies are warranted validating constructed population
PK models
• Future studies combining PK with pharmacodynamic data (e.g.
bleeding events, global hemostatic test results)
• Simulation analyses to objectify minimal FVIII and FIX levels re-
quired for adequate hemostasis in individual patients and speciﬁc
patient populations.
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